Silence Therapeutics (SLN) executive compensation, 2026 proxy

Iain Ross, Interim Principal Executive Officer, was paid $1.3M in 2025.

Filed
April 29, 2026
Annual meeting
June 16, 2026
Pay year
2025
Named executives
4
CEO total pay
$1.3M2025
Interim CEO Option Grant
900,000Granted December 18, 2025
2025 Corporate Scorecard Achievement
76%Based on strategic priorities

How Ross was paid

$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary1%Option awards99%

Named executive officers

ExecutiveTotal
Iain RossInterim Principal Executive Officer$1,274,041
Craig ToomanFormer Chief Executive Officer$2,246,863
Rhonda HellumsExecutive Vice President, Chief Financial Officer$1,150,923
Steven Romano, M.D.Executive Vice President, Chief of Research and Development$981,902

What changed and why

  • Iain Ross was appointed as interim principal executive officer on December 14, 2025.
  • $3.7MCraig Tooman total compensation decreased from $3,693,970 in 2024 to $2,246,863 in 2025.
  • 8.4%Rhonda Hellums base salary increased 8.4% to $490,000 for fiscal 2025.
  • 76%Corporate scorecard achievement for 2025 was determined to be 76% of target.
  • Annual equity grants were issued entirely in the form of share options.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.